证券代码：301257 证券简称：普蕊斯 普蕊斯（上海）医药科技开发股份有限公司 投资者关系活动记录表 编号：2026-001 投资者关系 活动类别 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位 名称及人员 姓名 汇添富基金 华夏基金 万家基金 信达澳亚基金 慎知资产 人保养老 建投基金 华泰保兴基金 太平洋保险 财通资管 农银汇理 中邮证券 华泰证券 华创证券 东方证券 国联民生证券 招商证券共 17 家机构 20 人 时间 2026 年 1 月 6 日、2026 年 1 月 9 日、2026 年 1 月 12 日—2026 年 1 月 13 日、2026 年 1 月 16 日 地点 上海公司会议室 上市公司接 待人员姓名 董事会秘书 赖小龙 投资者关系 活动主要 内容介绍 一、介绍公司基本情况 普蕊斯是一家大数据驱动型临床研究服务商，始终秉持"以 患者为中心"的理念，通过将临床试验和医院实际场景进行解 构，创建出一套临床试验全流程项目管理体系，公司深耕临床试 验现场管理组织（SMO）业务，致力于为中国临床试验执行提 质增效，助力新药更快惠及患 ...

Company Overview - Proris is a big data-driven clinical research service provider focused on creating a comprehensive project management system for clinical trials, emphasizing a patient-centered approach [1][2] - As of Q3 2025, the company achieved a revenue of CNY 219 million, representing a year-on-year growth of 9.84% [2] - The net profit for Q3 2025 was CNY 69.67 million, a significant increase of 120.72% compared to the previous year [2] Financial Performance - For the first three quarters of 2025, the total revenue reached CNY 609 million, with a year-on-year growth of 2.59% [2] - The net profit for the first three quarters was CNY 67.67 million, reflecting an 11.48% increase year-on-year [2] - The company distributed cash dividends totaling CNY 5.37 million in 2025, demonstrating a commitment to shareholder returns [4] Market Position and Competitive Landscape - The SMO industry is experiencing a concentration of resources towards leading firms, with increased competition characterized by: - Leading SMO companies expanding their client resources, professional talent, and research coverage [3] - Smaller SMOs gradually exiting the market, leading to increased industry concentration [3] - Proris has established partnerships with major global pharmaceutical companies and CROs, enhancing its service capabilities in innovative drug projects [4] Project Execution and Areas of Expertise - As of September 2025, Proris has undertaken over 4,200 clinical projects, with 2,538 currently in execution, covering various disease areas including hematological tumors, solid tumors, and rare diseases [4] - The company has a competitive advantage in several therapeutic areas, including cardiovascular diseases and endocrine disorders [4] Digital Transformation and Efficiency - Proris is focused on integrating digital technologies into its operations to enhance efficiency and service quality [6] - The company has developed a robust quality management system that supports cost reduction and efficiency improvements [4][6]

Company Overview - Prasis is a data-driven clinical research service provider focused on patient-centered approaches, creating a comprehensive project management system for clinical trials [2] - As of Q3 2025, the company achieved revenue of CNY 219 million, a year-on-year increase of 9.84% [2] - The net profit for Q3 2025 was CNY 33.22 million, a significant increase of 3,322.54% year-on-year, with a non-GAAP net profit of CNY 31.13 million, up 120.72% [2] Operational Highlights - The company has undertaken over 4,200 SMO projects, with 2,538 currently in execution, and employs 4,271 staff [2] - The service network covers over 1,300 clinical trial institutions across multiple cities in China [2] - For the first three quarters of 2025, the profit distribution plan included cash dividends totaling CNY 5.37 million [2] Quality Management - The company has established over 280 standard operating procedures (SOPs) and 40 negative lists to ensure quality control [3] - Continuous training and assessment of employees, along with an internal quality control team, enhance project oversight [3] - No major findings were reported during inspections by national and international regulatory bodies [3] Digital Transformation - The company prioritizes the development and application of digital and intelligent technologies as a key growth strategy [3] - A collaborative clinical trial management platform is being developed, integrating AI and advanced quality management systems for improved efficiency [3] Client Structure and Revenue Recognition - The client base primarily consists of multinational pharmaceutical companies, domestic innovative drug companies, and CROs, with significant collaborations with the top 10 global pharmaceutical companies [3] - Clinical trial project cycles typically last 2-3 years, with revenue recognition influenced by various factors, leading to non-linear income distribution [3] Recruitment and Talent Development - As of September 2025, the company has a workforce of 4,271, with over 4,000 specialized personnel [3] - Recruitment plans are aligned with project needs and are supported by a robust training system to ensure quality [4]

Group 1: Company Overview and Financial Performance - Prasis is a data-driven clinical research service provider focused on enhancing clinical trial execution in China, achieving a revenue of CNY 219 million in Q3 2025, a year-on-year increase of 9.84% [2] - For the first three quarters of 2025, the company reported a total revenue of CNY 1.1 billion, reflecting a growth of 6.09%, with a net profit of CNY 87.38 million, up 20.92% [2] - The company distributed cash dividends totaling CNY 5.37 million to shareholders, sharing the development results [2] Group 2: Market Trends and Order Growth - The Chinese innovative drug industry is entering a new phase of high-quality development, driven by policy support and active overseas licensing transactions, leading to a 2.59% increase in new orders [3] - The company has seen a significant increase in new orders from domestic pharmaceutical companies, particularly in oncology projects, which accounted for 39% of global oncology trials in 2024 [3][4] - The number of new projects and contract amounts is expected to grow due to the active overseas licensing collaborations, with over 100 license-out transactions and a total transaction amount exceeding USD 100 billion from January to October 2025 [5] Group 3: Operational Efficiency and Quality Management - The company has implemented a systematic quality management system, including over 280 standard operating procedures (SOPs) and 40 negative lists, ensuring no major findings during inspections by regulatory bodies [7] - Digital transformation initiatives are underway to enhance service efficiency and human resource effectiveness, integrating artificial intelligence and other new technologies [8] - Cost control measures include optimizing organizational structure and enhancing internal performance assessments to improve employee productivity [8] Group 4: Competitive Landscape and Industry Dynamics - The SMO industry is experiencing a concentration of resources towards leading firms, with smaller companies gradually exiting the market due to increased competition and regulatory demands [6] - Large pharmaceutical companies prefer stable, well-networked suppliers capable of managing complex clinical trial projects, which emphasizes the importance of quality and operational capability [6] - The regulatory environment is evolving, with stricter oversight and alignment with international standards, further highlighting the advantages of systematic and standardized operations [6]

Core Viewpoint - WuXi AppTec (02359) announced a sale agreement where its wholly-owned subsidiary, Shanghai WuXi AppTec New Drug Development Co., Ltd., will sell its shares in Shanghai Kande Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd. to Hillhouse Capital for cash consideration, reflecting the company's strategic focus on its core CRDMO business model [1] Group 1 - The transaction is expected to provide financial support to accelerate global capabilities and capacity development, enhancing service to clients and benefiting global patients [1] - Hillhouse Capital is recognized as a leading global private asset management firm, focusing on sectors such as healthcare, manufacturing, green energy, hard technology, and consumer technology [1] Group 2 - From January to September 2025, Kande Hongyi and Jinshi Pharmaceutical generated a total revenue of RMB 1.16 billion (unaudited), accounting for approximately 3.5% of the company's unaudited revenue for the first three quarters of 2025 [1] - During the same period, the net profit from Kande Hongyi and Jinshi Pharmaceutical amounted to RMB 90 million (unaudited), representing about 0.7% of the company's unaudited net profit for the first three quarters of 2025 [1]

Group 1 - The acquisition involves a total consideration of RMB 270 million, with the target company becoming a wholly-owned subsidiary of the acquiring company after the transaction [1] - The target company specializes in clinical trial technology services and related laboratory services, enhancing the acquiring company's global laboratory service capabilities and influence in China [2] - The acquisition is expected to strengthen the acquiring company's position as a trusted partner in the clinical research industry by expanding its center laboratory services in China and the Asia-Pacific region [2] Group 2 - The target group has extensive experience supporting over 1,500 clinical trials across multiple therapeutic areas and is known for its compliance with Good Clinical Practice (GCP) [2] - The acquisition will enhance the ability to provide high-quality one-stop services to pharmaceutical companies, contract research organizations, and research institutions [2] - The target company's successful track record includes contributions to the successful launch of 35 new drugs and support for regulatory audits [2]

Core Viewpoint - The acquisition of 100% equity in Shanghai Guanhua Medical Technology Co., Ltd. by Fangda Holdings aims to enhance the group's global laboratory service capabilities and strengthen its influence in China [1][2] Group 1: Acquisition Details - Fangda Holdings' wholly-owned subsidiary, Fangda Shanghai, plans to acquire Shanghai Guanhua Medical Technology for a total consideration of RMB 270 million [1] - The target company specializes in clinical trial technology services, related services, and laboratory services [1] Group 2: Strategic Objectives - The acquisition is intended to expand the group's central laboratory services in China and enhance its influence in the Asia-Pacific region [1] - The target group has extensive experience supporting over 1,500 clinical trials across multiple therapeutic areas, known for its compliance with Good Clinical Practice (GCP) and internationally recognized services [1][2] Group 3: Synergy and Market Position - The target group's strong track record, including its role in the successful launch of 35 new drugs and support for regulatory audits, complements the existing expertise of the group [2] - The acquisition will enhance the group's ability to provide high-quality one-stop services to pharmaceutical companies, contract research organizations, and research institutions, further solidifying its position as a trusted partner in the clinical research industry [2]

Core Viewpoint - Jefferies analyst David Windley downgraded Icon PLC (ICLR.US) from "Buy" to "Hold" and reduced the target price from $220 to $175, citing excessive unfavorable factors facing the company [1] Group 1: Company Performance - Windley believes that despite Icon PLC's stock being "cheap," there may be further downward revisions to earnings expectations [1] - Ongoing channel surveys indicate that Icon PLC is losing market share, which undermines the growth momentum gained from winning four partnership agreements since the merger with PRA Health [1] Group 2: Financial Outlook - Jefferies estimates that the amount of customer order cancellations in the third quarter could approach $1 billion, with a possibility of maintaining high levels in the fourth quarter [1] Group 3: Company Overview - Icon PLC is a clinical research organization that provides outsourced research and development services for the biotechnology, pharmaceutical, and medical device industries, focusing on managing, developing, and analyzing clinical development-related projects [1]

Financial Performance - In 2024, the company achieved operating revenue of 803.73 million yuan, a year-on-year increase of 5.75% [1] - The net profit attributable to shareholders was 106.43 million yuan, a decrease of 21.01% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 83.47 million yuan, down 26.88% year-on-year, primarily due to increased personnel costs [1] - In Q1 2025, the company reported operating revenue of 176.47 million yuan, a decline of 4.37% year-on-year [2] - The net profit attributable to shareholders in Q1 2025 was 7.43 million yuan, a significant drop of 67.32% year-on-year [2] - The net profit after deducting non-recurring gains and losses in Q1 2025 was 4.83 million yuan, down 75.34% year-on-year [2] Contractual and Operational Metrics - As of the end of 2024, the company had a total non-tax contract amount of 1.889 billion yuan, a year-on-year increase of 0.38% [2] - The company signed new contracts worth 1 billion yuan in 2024 [2] - By March 31, 2025, the company had undertaken over 3,800 clinical trial projects, serving 1,300 clients across more than 200 cities [2] Industry Trends and Developments - From 2015 to 2024, the number of innovative drugs approved for the first time in China increased from 3 to 39, a growth of 12 times, positioning China as the second globally [3] - The number of innovative drugs that initiated clinical trials in China rose from 124 in 2015 to 704 in 2024, making China the leader globally [4] - In 2024, Chinese pharmaceutical companies achieved a historic breakthrough in licensing out, with total transaction amounts reaching 51.9 billion USD, including upfront payments of 4.1 billion USD [4] - In Q1 2025, there were 33 licensing out transactions, a year-on-year increase of 32%, with total transaction amounts reaching 36.6 billion USD, an increase of over 250% [4] Clinical Trial Registration - In 2024, the total number of registered clinical trials in China reached 4,900, a year-on-year increase of 13.9% [5] - Among these, 2,539 new drug clinical trials were registered, reflecting a 9.3% increase year-on-year [5] - Class 1 drugs accounted for 68.3% of the new drug clinical trials, with anti-tumor drugs making up 39% of the total [5]

Group 1: Company Overview and Financial Performance - Prasis is a data-driven clinical research service provider focused on patient-centered approaches, enhancing the quality and efficiency of clinical trials in China [2] - In 2024, the company achieved operating revenue of CNY 803.73 million, a year-on-year increase of 5.75%, while net profit attributable to shareholders decreased by 21.01% to CNY 106.43 million [2] - For Q1 2025, operating revenue was CNY 176.47 million, down 4.37%, with net profit of CNY 7.43 million, a significant decline of 67.32% [2] - The company’s non-taxable contract amount at the end of 2024 was CNY 1.88 billion, reflecting a year-on-year increase [2] Group 2: Business Operations and Market Position - As of March 31, 2025, Prasis has undertaken over 3,800 SMO projects, serving more than 960 clinical trial institutions across over 200 cities in China [2] - The company has a strong focus on innovative and high-clinical-value new drug projects, collaborating with major global pharmaceutical companies [3] - The company’s client base primarily consists of multinational pharmaceutical companies, domestic innovative drug companies, and CROs, with a significant emphasis on high-quality service delivery [3] Group 3: Industry Trends and Competitive Landscape - The SMO industry in China is entering a new development phase, with increasing concentration among leading firms due to enhanced client resources and regulatory support [3] - Smaller SMO companies are gradually exiting the market, leading to a higher industry concentration [3] - The company has competitive advantages in various disease areas, including oncology and cardiovascular diseases, with a strong track record in launching innovative drugs [4] Group 4: Future Outlook and Strategic Initiatives - Prasis plans to continue organizational management innovation and explore the application of AI and new technologies in clinical trial execution [3] - The company aims to optimize its recruitment structure and enhance training programs to build a robust talent pipeline for long-term development [4] - In 2024, the company signed new contracts worth CNY 1 billion, with a 33% increase in new orders in the second half of the year compared to the first half [3]